Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 19Recruiting 12Terminated 5Active not recruiting 5Withdrawn 3Unknown 3Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Prostatic Neoplasms, Castration-Resistant 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × abiraterone × Clear all
NCT06060587 2025-10-22

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Northwestern University

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05705700 2023-02-27

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03173859 2020-11-18

AERA

University of Athens

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡